Actuarial LFS among patients randomized to treatment with busulfan (Bu) or TBI for early disease (first remission or first chronic phase) or late disease (later stages). The survival curves are significantly different between groups with late disease (P = .009). Bu early versus Bu late, P < .001; TBI early versus TBI late, P < .055. Tic marks represent surviving patients.